Free Trial
NASDAQ:QURE

uniQure Q2 2024 Earnings Report

uniQure logo
$14.56 -0.34 (-2.28%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$14.46 -0.10 (-0.69%)
As of 05/30/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

uniQure EPS Results

Actual EPS
-$1.16
Consensus EPS
-$1.24
Beat/Miss
Beat by +$0.08
One Year Ago EPS
N/A

uniQure Revenue Results

Actual Revenue
$11.13 million
Expected Revenue
$3.47 million
Beat/Miss
Beat by +$7.66 million
YoY Revenue Growth
N/A

uniQure Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Thursday, August 1, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

uniQure's Q2 2025 earnings is scheduled for Thursday, August 7, 2025

uniQure Earnings Headlines

uniQure (NASDAQ:QURE) Earns "Buy" Rating from Chardan Capital
uniQure's (QURE) Buy Rating Reaffirmed at HC Wainwright
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to protect your 401(k), IRA, or pension from market chaos and currency collapse? The 2025 Wealth Protection Guide reveals a legal IRS strategy that may let you keep more of your retirement—regardless of what happens next. Trump’s warning was real. So is this opportunity.
uniQure Sees Unusually High Options Volume (NASDAQ:QURE)
See More uniQure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like uniQure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on uniQure and other key companies, straight to your email.

About uniQure

uniQure (NASDAQ:QURE) N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

View uniQure Profile

More Earnings Resources from MarketBeat